These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 30416973)

  • 1. A higher blood glucose level pre-breakfast in comparison to bedtime is a contraindication for intensification of prandial insulin therapy in patients with type 2 diabetes - The impact of a negative BeAM value.
    Siegmund T; Borck A; Zisman A; Bramlage P; Kress S
    J Clin Transl Endocrinol; 2018 Dec; 14():34-38. PubMed ID: 30416973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Difference Between Bedtime and Pre-Breakfast Plasma Glucose Levels Indicates the Need for Prandial Insulin in Basal Insulin-Treated Type 2 Diabetic Patients with Normal Fasting Glucose.
    Kress S; Borck A; Zisman A; Bramlage P; Siegmund T
    Diabetes Metab Syndr Obes; 2021; 14():1215-1222. PubMed ID: 33776458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized clinical trial comparing breakfast and bedtime administration of insulin glargine in children and adolescents with type 1 diabetes.
    Şimşek DG; Yıldız B; Asar G; Darcan S
    J Clin Res Pediatr Endocrinol; 2008; 1(1):15-20. PubMed ID: 21318060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BeAM value: an indicator of the need to initiate and intensify prandial therapy in patients with type 2 diabetes mellitus receiving basal insulin.
    Zisman A; Morales F; Stewart J; Stuhr A; Vlajnic A; Zhou R
    BMJ Open Diabetes Res Care; 2016; 4(1):e000171. PubMed ID: 27110368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs.
    Lankisch MR; Ferlinz KC; Leahy JL; Scherbaum WA;
    Diabetes Obes Metab; 2008 Dec; 10(12):1178-85. PubMed ID: 19040645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2).
    Zinman B; Marso SP; Poulter NR; Emerson SS; Pieber TR; Pratley RE; Lange M; Brown-Frandsen K; Moses A; Ocampo Francisco AM; Barner Lekdorf J; Kvist K; Buse JB;
    Diabetologia; 2018 Jan; 61(1):48-57. PubMed ID: 28913575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy.
    Yokoyama H; Tada J; Kamikawa F; Kanno S; Yokota Y; Kuramitsu M
    Diabetes Res Clin Pract; 2006 Jul; 73(1):35-40. PubMed ID: 16513202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Basal-prandial insulin delivery in type 2 diabetes mellitus via the V-Go: a novel continuous subcutaneous infusion device.
    Kapitza C; Fein S; Heinemann L; Schleusener D; Levesque S; Strange P
    J Diabetes Sci Technol; 2008 Jan; 2(1):40-6. PubMed ID: 19885176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.
    Rossetti P; Pampanelli S; Fanelli C; Porcellati F; Costa E; Torlone E; Scionti L; Bolli GB
    Diabetes Care; 2003 May; 26(5):1490-6. PubMed ID: 12716810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initiation of insulin glargine in suboptimally controlled patients with type 2 diabetes: sub-analysis of the AT.LANTUS trial comparing treatment outcomes in subjects from primary and secondary care in the UK.
    Davies M; Evans R; Storms F; Gomis R; Khunti K
    Diabetes Obes Metab; 2007 Sep; 9(5):706-13. PubMed ID: 17697063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of Hypoglycaemia in Patients with Type 2 Diabetes - A Subgroup Analysis from the GINGER study.
    Fritsche A; Hahn A; Landgraf W; Häring HU
    Eur Endocrinol; 2013 Mar; 9(1):1-3. PubMed ID: 30349602
    [No Abstract]   [Full Text] [Related]  

  • 12. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.
    Rosenstock J; Park G; Zimmerman J;
    Diabetes Care; 2000 Aug; 23(8):1137-42. PubMed ID: 10937511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adding Prandial Insulin to Basal Insulin Plus Oral Antidiabetic Drugs in Chinese Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Single-Arm Study.
    Jin Y; Sun X; Zhao X; Zhu T
    Diabetes Ther; 2017 Jun; 8(3):611-621. PubMed ID: 28349442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Switching from Twice-Daily Basal Insulin to Once-Daily Insulin Glargine 300 U/mL in People with Type 1 Diabetes on Basal-Bolus Insulin: Phase 4 OPTIMIZE Study.
    Mathieu C; Weisnagel SJ; Stella P; Bruhwyler J; Alexandre K
    Diabetes Ther; 2020 Feb; 11(2):495-507. PubMed ID: 31925722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of morning basal + 1 bolus insulin therapy (insulin glulisine + insulin glargine 300 U/mL vs insulin lispro + insulin glargine biosimilar) using continuous glucose monitoring: A randomized crossover study.
    Takeishi S; Tsuboi H; Takekoshi S
    J Diabetes Investig; 2018 Jan; 9(1):91-99. PubMed ID: 28371461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs.
    Owens DR
    Diabet Med; 1998; 15 Suppl 4():S28-36. PubMed ID: 9868989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimates of the relative and absolute diurnal contributions of fasting and post-prandial plasma glucose over a range of hyperglycaemia in type 2 diabetes.
    Peter R; Dunseath G; Luzio SD; Owens DR
    Diabetes Metab; 2013 Sep; 39(4):337-42. PubMed ID: 23993831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fasting C-peptide, a biomarker for hypoglycaemia risk in insulin-naïve people with type 2 diabetes initiating basal insulin glargine 100 U/mL.
    Landgraf W; Owens DR; Frier BM; Zhang M; Bolli GB
    Diabetes Obes Metab; 2020 Mar; 22(3):315-323. PubMed ID: 31608548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of a basal-plus regimen with insulin glargine and insulin glulisine for elderly patients with high cardiovascular risk and type 2 diabetes mellitus.
    Gómez-Huelgas R; Sabán-Ruiz J; García-Román FJ; Quintela-Fernández N; Seguí-Ripoll JM; Bonilla-Hernández MV; Romero-Meliá G
    Rev Clin Esp (Barc); 2017 May; 217(4):201-206. PubMed ID: 28314656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and Safety of Switching Rapid-Acting Insulins to Insulin Glulisine in Patients with Diabetes: The Observational IGLU-S Study.
    Seufert J; Pfohl M; Borck A; Bramlage P; Siegmund T
    Diabetes Ther; 2021 Mar; 12(3):749-764. PubMed ID: 33544356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.